Efficacy and Safety Of AXS-05 in Agitation Associated with Alzheimer’s Disease: Results from ACCORD, a Phase 3, Double-blind, Placebo-controlled, Relapse Prevention Trial (PL5.004)

To evaluate AXS-05 (dextromethorphan-bupropion), an oral NMDA receptor antagonist/sigma-1 receptor agonist FDA approved for major depressive disorder, for the treatment of Alzheimer's disease (AD) associated agitation (A).